The Commonwealth in Limbo: How Virginia Built a Cannabis Market for Everyone Except Cannabis Companies
Five years after becoming the first Southern state to legalize, Virginia still has no legal way to buy weed. On May 19, 2026, Gov. Abigail Spanberger — who campaigned on signing exactly this bill — became the third Virginia governor in a row to veto retail cannabis, this time against her own party's trifecta. The story runs through Total Wine's hemp-THC lobby, an FBI raid on Sen. Louise Lucas's dispensary, $700M in forgone tax revenue bleeding to Maryland, and a regulator built to regulate nothing. The earliest plausible adult-use retail launch in Virginia is now 2028.
The $99 Million Line Item Curaleaf Doesn't Want You to Overthink
Curaleaf's $70M Q1 profit was a 280E reversal in disguise — strip out the $98.7M one-time tax benefit and pre-tax operating losses actually widened 74% year-over-year. The headline beat masks compressing margins, a 1.3% FCF margin, and an 11.5% bond coupon. The real story is structural: a BDO auditor swap, DEA registration filings, the completed Four 20 Pharma consolidation, and a quiet domestic wholesale pivot. Curaleaf is methodically rebuilding its infrastructure for a major-exchange uplisting.
The MSOS Black Box: How a Cannabis ETF Actually Works
More than 60% of MSOS isn't stock — it's a stack of total return swaps written by five broker-dealers, collateralized by money-market cash, referencing securities listed in Canada and hedged through positions you can't see. A deep dive into the strangest ETF on the NYSE: who the five counterparties actually are, why your buy order at Schwab moves the price of CSE-listed shares, and what April's Schedule III order does (and doesn't) change about the structure.
The MSO Uplisting Question: Why Nobody Agrees, and What's Actually True
Zero US plant-touching MSOs trade on NYSE or NASDAQ — and SAFE Banking, the April 2026 partial rescheduling, and Trulieve's Delaware move don't change that on their own. A deep dive into where MSOs actually trade, the NASDAQ Rule 5101 wall, the MSOS swap book held together by five non-US-bank counterparties, and the three-layered stack of events (broader rescheduling + CLIMB-style safe harbor + exchange policy revision) that has to clear before the first uplisting. Base case: late 2027 to mid-2028.
From Congo Square to Cinema Village: The Quiet Triumph of Cannabis! A Viper Vaudeville
Baba Israel and Grace Galu have spent four years turning Martin A. Lee's Smoke Signals into a touring music-theater piece that puts Black cultural authorship at the center of the cannabis story. In April it played a sold-out preview at Nublu; in May the accompanying documentary opened at Cinema Village. The most interesting cultural artifact of the legalization era isn't on a dispensary shelf — it's on stage.
The road to Schedule III
Tracking every step of the federal rescheduling process — from Biden's 2022 review order through Trump's executive action and the April 23 DOJ order moving medical cannabis to Schedule III, to the June 29 Phase Two hearing on full rescheduling.
Six a.m. Eastern. Before the market opens.
One email. The night's moves, the morning's agenda, and three things every operator needs to know before 9:30.